98977-37-8

Basic information

• Product Name: ETHYL 1-BOC-4-OXO-3-AZEPANECARBOXYLATE
• Synonyms: ETHYL 1-BOC-4-OXO-3-AZEPANECARBOXYLATE;1-tert-Butyl 3-ethyl 4-oxoazepane-1,3-dicarboxylate
• CAS NO: 98977-37-8
• Molecular Formula: C₁₄H₂₃NO₅
• Molecular Weight: 285.34
• Product Categories: pharmacetical
• Mol File: 98977-37-8.mol

Chemical Properties

• Boiling Point: 380.8°Cat760mmHg
• Flash Point: 184.1°C
• Appearance: /
• Density: 1.127g/cm³
• Vapor Pressure: 5.33E-06mmHg at 25°C
• Refractive Index: 1.479
• PKA: 11.08±0.20(Predicted)
• CAS DataBase Reference: ETHYL 1-BOC-4-OXO-3-AZEPANECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 1-BOC-4-OXO-3-AZEPANECARBOXYLATE(98977-37-8)
• EPA Substance Registry System: ETHYL 1-BOC-4-OXO-3-AZEPANECARBOXYLATE(98977-37-8)

Safety Data

• Hazardous Substances Data: 98977-37-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H23NO5/c1-5-19-12(17)10-9-15(8-6-7-11(10)16)13(18)20-14(2,3)4/h10H,5-9H2,1-4H3

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 851593-77-6 (-)-1-(tert-butoxycarbonyl)azepane-3-carboxylic acid 
• 1023954-34-8 C₂₀H₂₅N₃O₃ 

Relevant articles and documents

Pyrimidine derivative and application thereof in medicines

The invention discloses a pyrimidine derivative and application thereof in medicines, and particularly relates to a novel pyrimidine derivative and a pharmaceutical composition containing the compound. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in preparation of drugs for treating KRAS G12C-mediated diseases and/or symptoms, especially in preparation of drugs for treating cancers.

7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME

The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.

Synthesis of azabicyclo[n.1.0]alkane-derived bifunctional building blocks via the Corey–Chaykovsky cyclopropanation

An efficient approach towards the synthesis of monoprotected azabicyclo[5.1.0]octane-derived conformationally restricted γ-amino acids and diamines is reported. Optimization of the conditions for the key Corey–Chaykovsky reaction allowed the construction

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS

Certain 2-aminopyrimidine compounds are serotonin receptor modulators useful in the treatment of diseases mediated by serotonin receptors.

2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists

The synthesis and SAR for a novel series of 2-alkyl-4-aryl-tetrahydro-pyrido-pyrimidines and 2-alkyl-4-aryl-tetrahydro-pyrimido-azepines is described. Representative compounds were shown to be subtype selective 5-HT2A antagonists. Optimal place

PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS

Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases.

Assymetric synthesis of azepines

A novel process for the manufacture of compounds of the formula STR1 wherein R1 and R2 independently represent aroyl. The present invention also concerns novel intermediates used in the novel process for making compounds of formula I.

Glycine Antagonists. Synthesis, Structure, and Biological Effects of Some Bicyclic 5-Isoxazolol Zwitterions

The bicyclic 5-isoxazolol zwitterions 4,5,6,7-tetrahydroisoxazolopyridin-3-ol (3, iso-THPO), 5,6,7,8-tetrahydro-4H-isoxazoloazepin-3-ol (12, iso-THAO), and 5,6,7,8-tetrahydro-4H-isoxazoloazepin-3-ol (13, iso-THIA), which are structurally related to the glycine antagonist 5,6,7,8-tetrahydro-4H-isoxazoloazepin-3-ol (iso-THAZ), have been synthesized and tested biologically.All of these compounds were glycine antagonists approximetely equipotent with iso-THAZ during microelectrophoretic ejection near cat spinal neurons.In contrast to iso-THAZ, which also interacts with 4-aminobutyric acid (GABA) receptors in rat brains, neither 12 or 13 show any significant affinities for GABA binding or uptake mechanisms in vitro.The glycine antagonist 3 was, however, shown also to be a moderately potent inhibitor of GABA uptake.The structure of 12 was established by an X-ray analysis.The bond lengths of the 5-isoxazolol anionic moiety of 12 are in agreement with a pronounced delocalization of the negative charge of this compound.